

Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis

NCT07488728

Status	RECRUITING
Phase	Not Applicable
Sponsor	Beijing Children's Hospital
Enrollment	80 participants

Key Eligibility Criteria

Inclusion (5)

- Diagnosed with EBV-positive T/NK lymphoproliferative disease (EBV-T/NK LPD) according to ICC 2022 criteria, or diagnosed with refractory/relapsed EBV-associated hemophagocytic lymphohistiocytosis (EBV-HLH) according to the 2004-HLH diagnostic criteria;
- Undergoing first allogeneic hematopoietic stem cell transplantation (allo-HSCT) at the study center;
- Age \leq 18 years;
- CMV seropositive (IgG+) prior to transplantation;
- Presence of at least one high-risk factor for CMV infection: haploidentical transplantation, HLA-mismatched transplantation, receipt of ATG (including ATLG/ALG) in conditioning, sustained corticosteroid use post-conditioning, donor/recipient CMV serostatus mismatch, or positive NGS result pre-transplant.

Exclusion (9)

- History of CMV end-organ disease within 6 months prior to enrollment;
- Severe hepatic dysfunction (defined as Child-Pugh Class C);
- End-stage renal impairment with creatinine clearance \leq 10 mL/min (calculated by Cockcroft-Gault equation);
- Prior allogeneic hematopoietic stem cell transplantation;
- Expected survival \leq 3 months;
- ... and 4 more (see full listing online)

Locations (1 total)

Beijing Children's Hospital, Capital Medical University, Beijing, Beijing Municipality, China

<https://clinicaltrials.gov/study/NCT07488728>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).